Biocartis

Researchers separately found that the assay had high concordance with other techniques in cancers including colorectal and endometrial carcinomas.

The firm reported a 69 percent increase in product sales, driven by a 102 percent jump in cartridge sales and jump in research revenues.  

The two firms will provide €14M ($16.2 million) of equity funding to commercialize the Idylla platform in the Chinese market.

The agreement will enable Biocartis to commercialize the EGFR S492R resistance mutation as part of its liquid and solid biopsy RUO assays.

The firm said it plans to accelerate the expansion of its test menu through partnerships with pharma and biotech companies.

Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.

Running on the Biocartis Idylla platform, Immunexpress' Septicyte test will detect sepsis in patients in as little as an hour.

Biocartis will help develop and commercialize Immunexpress' Septicyte test to run on the Idylla platform.

The companies are aiming to develop Idylla-based CDx biomarker tests for a compound Amgen is developing to treat solid tumors.

The companies are seeking to register Biocartis' Idylla RAS biomarker tests with the FDA as companion diagnostics for Amgen's Vectibix.

Pages

Researchers in the UK and Australia uncover genetic links between BMI and depression, the Guardian reports.

The Verge details the account of an academic who alleges her university retaliated against her after she complained of sexual harassment by her supervisor.

The New York Times writes that natural history museums are helping round out genetic studies with older specimens.

In PNAS this week: artemisinin resistance mutations in malaria parasites, ant-plant interactions over time, and more.